EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations

Caicun Zhou, Laurent Greillier, Geoffrey Liu, Thomas John, Ligang Xing, Dariusz Kowalski, Regan M Memmott, Ozan Yazici, Meili Sun, Catherine A Shu, Elvire Pons-Tostivint, Yun Fan und 19 weitere

New England Journal of Medicine · 20.08.2026 · 395 (8) · 765-775

DOI: 10.1056/nejmoa2604461 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 20.08.2026. Verfasst von Caicun Zhou und 30 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai East Hospital, Shanghai. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutagenesis, Insertional. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Dizal Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsMutagenesis, InsertionalAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinErbB ReceptorsExonsKaplan-Meier EstimatePemetrexedProgression-Free SurvivalAcrylamidesPyrrolidinesTyrosine Kinase InhibitorsDiarrheaAnemia

Substanzen

Antineoplastic AgentsCarboplatinEGFR protein, humanErbB ReceptorsPemetrexedsunvozertinibAcrylamidesPyrrolidinesTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Shanghai East Hospital, Shanghai.
  • Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France.
  • Princess Margaret Cancer Centre, University Health Network, Toronto.
  • Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Shandong Cancer Hospital, Jinan, China.
  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Klinika Nowotworow Pluca i Klatki Piersiowej, Warsaw, Poland.

Förderung

  • Dizal Pharmaceuticals

Zitieren

APA

Zhou, C., Greillier, L., Liu, G., John, T., Xing, L., Kowalski, D., Memmott, R. M., Yazici, O., Sun, M., Shu, C. A., Pons-Tostivint, E., Fan, Y., Fernandez-Hinojal, G., Shum, E., Wang, M., Bertolini, F., Camidge, D. R., Zhou, C., Doucet, L., …, & WU-KONG28 Investigators (2026). First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. New England Journal of Medicine, 395(8), 765-775. https://doi.org/10.1056/nejmoa2604461

Vancouver

Zhou C, Greillier L, Liu G, John T, Xing L, Kowalski D, et al. First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. New England Journal of Medicine. 2026;395(8):765-775. doi:10.1056/nejmoa2604461

BibTeX
@article{Zhou2026,
  author = {Zhou, Caicun and Greillier, Laurent and Liu, Geoffrey and John, Thomas and Xing, Ligang and Kowalski, Dariusz and Memmott, Regan M and Yazici, Ozan and Sun, Meili and Shu, Catherine A and Pons-Tostivint, Elvire and Fan, Yun and Fernandez-Hinojal, Gonzalo and Shum, Elaine and Wang, Mengzhao and Bertolini, Federica and Camidge, D Ross and Zhou, Chengzhi and Doucet, Ludovic and Hong, Qunying and Fang, Jian and Huang, Dingzhi and Jin, Bo and Yu, Yan and Antonuzzo, Lorenzo and Moro-Sibilot, Denis and Bennouna, Jaafar and de Castro, Gilberto and Zheng, Li and Heymach, John V and WU-KONG28 Investigators, WU-KONG28 Investigators},
  title = {First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {8},
  pages = {765--775},
  doi = {10.1056/nejmoa2604461}
}
Kostenlos starten →